|1.||Ostádal, B: 1 article (01/2005)|
|2.||Neckár, J: 1 article (01/2005)|
|3.||Kolár, F: 1 article (01/2005)|
|4.||Akao, Masaharu: 1 article (03/2003)|
|5.||Ohler, Andreas: 1 article (03/2003)|
|6.||Guo, Yiru: 1 article (03/2003)|
|7.||Xiao, Rui-Ping: 1 article (03/2003)|
|8.||Jo, Su-Hyun: 1 article (03/2003)|
|9.||Murata, Mitsushige: 1 article (03/2003)|
|10.||Bolli, Roberto: 1 article (03/2003)|
01/01/2005 - "MCC-134 was administered intravenously 10 min before ischemia and 5 min before reperfusion in a total dose of 0.3 mg/kg or 3 mg/kg divided into two equal boluses. "
03/04/2003 - "MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. "
03/04/2003 - "In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. "
01/01/2005 - "Both doses of MCC-134 completely abolished the antiarrhythmic protection (score 2.4+/-0.7 and 2.5+/-0.5, respectively) but only the high dose blocked the infarct size-limiting effect of chronic hypoxia (54.2+/-3.7 %). "
01/01/2005 - "MCC-134, a blocker of mitochondrial and opener of sarcolemmal ATP-sensitive K+ channels, abrogates cardioprotective effects of chronic hypoxia."
01/01/2005 - "We examined the effect of MCC-134, a novel inhibitor of mitochondrial ATP-sensitive K(+) (mitoK(ATP)) channels and activator of sarcolemmal ATP-sensitive K(+) (sarcK(ATP)) channels, on cardioprotection conferred by adaptation to chronic hypoxia. "
|2.||Adenosine Triphosphate (ATP)
|3.||mitochondrial K(ATP) channel